{
    "hands_on_practices": [
        {
            "introduction": "The diagnosis of an insulinoma rests on the biochemical confirmation of endogenous hyperinsulinemic hypoglycemia. This exercise  provides a classic clinical scenario, challenging you to apply the standardized diagnostic criteria from a supervised fast. Mastering this process is a foundational skill for correctly identifying patients who require surgical localization and treatment for this functional pancreatic neuroendocrine tumor.",
            "id": "4652669",
            "problem": "A patient with recurrent fasting neuroglycopenic symptoms undergoes a supervised fast. At symptom onset, simultaneous plasma measurements are obtained: $[\\text{glucose}]=45\\,\\text{mg/dL}$, $[\\text{insulin}]=6\\,\\mu\\text{U/mL}$, $[\\text{C-peptide}]=0.3\\,\\text{nmol/L}$, and $[\\text{proinsulin}]=15\\,\\text{pmol/L}$. A comprehensive sulfonylurea and meglitinide screen is negative. Using the standard, widely accepted biochemical criteria for endogenous hyperinsulinemic hypoglycemia in insulinoma during a supervised fast, define the diagnostic indicator $D$ by $D=1$ if the criteria are met and $D=0$ otherwise. Compute $D$. The final answer must be a single real number with no units. No rounding is required.",
            "solution": "The user wants me to solve a problem.\n\n**Problem Validation**\n\n**Step 1: Extract Givens**\n\nThe problem provides the following information about a patient with recurrent fasting neuroglycopenic symptoms who underwent a supervised fast:\n-   At symptom onset, simultaneous plasma measurements were:\n    -   $[\\text{glucose}] = 45\\,\\text{mg/dL}$\n    -   $[\\text{insulin}] = 6\\,\\mu\\text{U/mL}$\n    -   $[\\text{C-peptide}] = 0.3\\,\\text{nmol/L}$\n    -   $[\\text{proinsulin}] = 15\\,\\text{pmol/L}$\n-   A comprehensive sulfonylurea and meglitinide screen is negative.\n-   A diagnostic indicator $D$ is defined as $D=1$ if the standard biochemical criteria for endogenous hyperinsulinemic hypoglycemia in insulinoma are met, and $D=0$ otherwise.\n-   The task is to compute the value of $D$.\n\n**Step 2: Validate Using Extracted Givens**\n\nThe problem is evaluated against the established criteria for validity:\n\n-   **Scientifically Grounded:** The problem is firmly rooted in the established clinical and biochemical principles of endocrinology and general surgery for the diagnosis of insulinoma. The concept of a supervised fast, the measurement of glucose, insulin, C-peptide, and proinsulin, and the use of a drug screen are all standard-of-care diagnostic procedures. The provided values are clinically plausible.\n-   **Well-Posed:** The problem gives a complete set of data and a clear, unambiguous task: to apply a well-defined set of diagnostic criteria. The criteria for diagnosing endogenous hyperinsulinemic hypoglycemia are standardized in medical literature, leading to a unique and meaningful solution.\n-   **Objective:** The problem is based on objective, quantitative laboratory measurements and asks for an evaluation against \"standard, widely accepted biochemical criteria,\" which are objective and not subject to opinion.\n\nThe problem exhibits none of the flaws that would render it invalid. It is scientifically sound, well-posed, objective, complete, and directly relevant to the specified topic.\n\n**Step 3: Verdict and Action**\n\nThe problem statement is **valid**. Proceeding with the solution.\n\n**Solution**\n\nThe objective is to determine the value of the diagnostic indicator $D$ based on whether the patient's laboratory results meet the standard criteria for endogenous hyperinsulinemic hypoglycemia, which is the hallmark of an insulinoma. The diagnosis requires the presence of hypoglycemia accompanied by inappropriately high levels of insulin and its precursors, with exclusion of exogenous causes. We will evaluate the given data against each criterion.\n\nThe standard diagnostic criteria, often evaluated at the end of a supervised fast when symptoms of neuroglycopenia occur, are as follows:\n\n1.  **Plasma Glucose:** A low plasma glucose level is required, typically defined as $[\\text{glucose}] < 55\\,\\text{mg/dL}$.\n    -   The patient's measured glucose is $[\\text{glucose}] = 45\\,\\text{mg/dL}$.\n    -   Since $45 < 55$, this criterion is met.\n\n2.  **Plasma Insulin:** In a healthy individual, hypoglycemia strongly suppresses insulin secretion. An inappropriately elevated insulin level is a key diagnostic feature. The threshold is typically $[\\text{insulin}] \\ge 3\\,\\mu\\text{U/mL}$.\n    -   The patient's measured insulin is $[\\text{insulin}] = 6\\,\\mu\\text{U/mL}$.\n    -   Since $6 \\ge 3$, this criterion is met. The insulin level is inappropriately high for the degree of hypoglycemia.\n\n3.  **Plasma C-peptide:** C-peptide is co-secreted with endogenous insulin in equimolar amounts. A normal or elevated C-peptide level in the setting of hyperinsulinemic hypoglycemia confirms an endogenous source of insulin (i.e., from the patient's own pancreas) and rules out the surreptitious administration of exogenous insulin. The threshold is typically $[\\text{C-peptide}] \\ge 0.2\\,\\text{nmol/L}$ (equivalent to $0.6\\,\\text{ng/mL}$).\n    -   The patient's measured C-peptide is $[\\text{C-peptide}] = 0.3\\,\\text{nmol/L}$.\n    -   Since $0.3 \\ge 0.2$, this criterion is met.\n\n4.  **Plasma Proinsulin:** Insulinomas are often inefficient at processing proinsulin to mature insulin, leading to a disproportionate secretion of proinsulin. An elevated proinsulin level is highly suggestive of an insulinoma. A common diagnostic threshold is $[\\text{proinsulin}] \\ge 5\\,\\text{pmol/L}$.\n    -   The patient's measured proinsulin is $[\\text{proinsulin}] = 15\\,\\text{pmol/L}$.\n    -   Since $15 \\ge 5$, this criterion is met.\n\n5.  **Screen for Hypoglycemic Agents:** It is crucial to exclude factitious hypoglycemia caused by insulin secretagogues like sulfonylureas or meglitinides. These drugs stimulate endogenous insulin and C-peptide secretion, mimicking the biochemical profile of an insulinoma.\n    -   The problem states that the \"comprehensive sulfonylurea and meglitinide screen is negative.\"\n    -   This criterion is met, ruling out these specific exogenous causes.\n\nAll five biochemical criteria for establishing a diagnosis of endogenous hyperinsulinemic hypoglycemia, consistent with an insulinoma, are satisfied by the patient's data. Therefore, according to the problem's definition, the diagnostic indicator $D$ must be assigned the value $1$.\n\nThe final computation is:\n-   Hypoglycemia confirmed: $45 < 55$.\n-   Inappropriate hyperinsulinemia confirmed: $6 \\ge 3$.\n-   Endogenous source confirmed by C-peptide: $0.3 \\ge 0.2$.\n-   Inefficient processing confirmed by proinsulin: $15 \\ge 5$.\n-   Exogenous drug stimulation excluded: Negative screen.\n\nSince all conditions are met, $D=1$.",
            "answer": "$$\\boxed{1}$$"
        },
        {
            "introduction": "Once a pancreatic neuroendocrine tumor is identified, its biological behavior is best predicted by histopathologic grading. This practice  guides you through the essential steps of calculating the Ki-67 proliferation index and assigning a formal WHO grade. More critically, it tasks you with connecting this grade to core principles of surgical oncology to inform the choice between a parenchyma-sparing procedure and a formal oncologic resection.",
            "id": "5163793",
            "problem": "A surgical pathology report for a pancreatic neuroendocrine tumor (pNET) provides a manual hotspot count of $2000$ tumor nuclei, with $120$ nuclei positive for the Ki-67 antigen by immunohistochemistry. Using the core definition that the Ki-67 index is the fraction of Ki-67 positive tumor nuclei among the total tumor nuclei counted, derive the Ki-67 index as a decimal fraction. Then, using the World Health Organization (WHO) 2017/2019 grading thresholds for pancreatic neuroendocrine tumors based on Ki-67 index (Grade $1$: Ki-67 index $< 0.03$, Grade $2$: Ki-67 index in $[0.03, 0.20]$, Grade $3$: Ki-67 index $> 0.20$), assign the WHO grade from first principles. Finally, discuss from first principles how this grade informs operative strategy selection in systemic surgery for pNETs (for example, the choice between parenchyma-sparing enucleation versus formal oncologic resection with lymphadenectomy), grounding your reasoning in well-tested oncologic surgical principles such as the relationship between proliferative activity, nodal metastasis risk, and the goal of complete margin-negative resection.\n\nTo ensure a single numeric final answer, define the aggregated metric $S$ by\n$$S \\equiv G + I,$$\nwhere $I$ is the Ki-67 index expressed as a decimal fraction and $G \\in \\{1,2,3\\}$ is the numerical code for the assigned WHO grade (Grade $1 \\mapsto G=1$, Grade $2 \\mapsto G=2$, Grade $3 \\mapsto G=3$). Compute $S$ from the given data. Round your final aggregated metric $S$ to four significant figures. Express your final answer as a pure number without units.",
            "solution": "The task begins with the core definition of the Ki-67 index for a tumor sample. The Ki-67 index $I$ is defined as the fraction of Ki-67 positive tumor nuclei among the total number of tumor nuclei counted. Let $n_{+}$ denote the number of Ki-67 positive nuclei and let $n_{\\text{tot}}$ denote the total number of tumor nuclei counted. The definition is\n$$\nI \\equiv \\frac{n_{+}}{n_{\\text{tot}}}.\n$$\nWe are given $n_{+} = 120$ and $n_{\\text{tot}} = 2000$. Substituting,\n$$\nI = \\frac{120}{2000}.\n$$\nWe simplify this fraction:\n$$\n\\frac{120}{2000} = \\frac{12}{200} = \\frac{3}{50}.\n$$\nThus,\n$$\nI = \\frac{3}{50} = 0.06.\n$$\n\nNext, we assign a World Health Organization (WHO) grade according to well-tested grading thresholds for pancreatic neuroendocrine tumors based on the Ki-67 index. The thresholds are:\n- Grade $1$: Ki-67 index $< 0.03$,\n- Grade $2$: Ki-67 index in $[0.03, 0.20]$,\n- Grade $3$: Ki-67 index $> 0.20$.\n\nOur computed $I = 0.06$ lies within the interval $[0.03, 0.20]$. Therefore, the WHO grade is Grade $2$. By the problem’s coding, this corresponds to\n$$\nG = 2.\n$$\n\nWe now discuss how this grade informs operative strategy in systemic surgery for pancreatic neuroendocrine tumors, grounding the reasoning in foundational surgical oncology principles rather than heuristic rules. The fundamental base includes:\n- The oncologic principle that higher proliferative activity (as measured by Ki-67 index) correlates with increased risk of lymph node metastasis and recurrence, which in turn motivates more comprehensive oncologic resections with lymphadenectomy to achieve complete margin-negative ($\\text{R}0$) resection and appropriate nodal staging.\n- The well-established distinction between parenchyma-sparing procedures (such as enucleation) and formal anatomical resections (such as distal pancreatectomy or pancreaticoduodenectomy) with lymphadenectomy, where the latter provide systematic nodal assessment and wider margins at the cost of greater parenchymal loss and morbidity.\n\nApplying these principles to a pNET with $I = 0.06$ (Grade $2$):\n- The Ki-67 index of $0.06$ indicates intermediate proliferative activity (higher than Grade $1$ and substantially lower than Grade $3$), which is associated with a nontrivial risk of lymph node involvement compared to Grade $1$ tumors. This elevates the importance of nodal assessment and achieving an oncologically sound margin.\n- Consequently, operative strategy should favor formal oncologic resection with regional lymphadenectomy for non-functioning lesions of clinically relevant size or location, to accomplish $\\text{R}0$ margins and accurate nodal staging. Parenchyma-sparing enucleation is more appropriate for small, well-differentiated Grade $1$ functioning tumors (for example, insulinomas) that are away from the main pancreatic duct and have low nodal risk; for Grade $2$, the higher proliferative index supports a shift toward anatomical resection over enucleation, unless exceptional circumstances (very small, clearly benign behavior, and safe distance from the duct) argue otherwise.\n- In summary, the Grade $2$ assignment informs a strategy prioritizing margin-negative anatomical resection with nodal sampling or dissection, rather than routine enucleation, consistent with the increased proliferative activity and corresponding oncologic risk profile.\n\nFinally, we compute the aggregated metric $S$ defined by the problem:\n$$\nS \\equiv G + I = 2 + 0.06 = 2.06.\n$$\nWe are instructed to round $S$ to four significant figures. The value $2.06$ expressed to four significant figures is\n$$\n2.060.\n$$\nThis is a pure number without units, satisfying the problem’s specification.",
            "answer": "$$\\boxed{2.060}$$"
        },
        {
            "introduction": "One of the most common and challenging questions in modern pancreatic surgery is the management of small, incidentally discovered, nonfunctional pNETs. This problem  presents a detailed clinical case that requires you to synthesize multiple data points—tumor size, grade, and location—to balance the risks of observation against the morbidity of surgery. This exercise hones the nuanced clinical judgment needed to craft a safe and effective, patient-centered management plan.",
            "id": "4652602",
            "problem": "A $58$-year-old individual undergoes abdominal imaging for nephrolithiasis and is incidentally found to have a well-circumscribed pancreatic tail lesion measuring $1.5\\,\\text{cm}$ on a pancreas-protocol multiphasic Computed Tomography (CT) scan. Magnetic Resonance Imaging (MRI) confirms a hyperenhancing $1.5\\,\\text{cm}$ lesion without main pancreatic duct dilation (main duct caliber $\\leq 3\\,\\text{mm}$), without abutment of the splenic artery or vein, and without suspicious peripancreatic lymph nodes. Endoscopic Ultrasound (EUS) with Fine-Needle Aspiration (FNA) shows a well-differentiated pancreatic neuroendocrine tumor (pNET) with a Ki-$67$ index of $2\\%$ and low mitotic activity, consistent with World Health Organization (WHO) grade $1$. Fasting serum hormone panel (insulin, glucagon, gastrin, vasoactive intestinal peptide, somatostatin) is normal, and the patient endorses no symptoms of hormone excess. There is no evidence of metastatic disease on cross-sectional imaging. The patient has well-controlled hypertension, no history of pancreatitis, and expresses willingness for close follow-up if clinically justified.\n\nUsing fundamental oncologic and surgical principles that relate tumor size, differentiation, and proliferative index to metastatic potential and growth kinetics, and balancing these against operative risks of distal pancreatectomy (including pancreatic fistula, endocrine and exocrine insufficiency, and splenic sequelae), which of the following option best specifies appropriate criteria for initial observation versus resection and delineates a scientifically sound surveillance and intervention plan for this patient?\n\nA. Offer active surveillance because the tumor is nonfunctional, $\\lt 2\\,\\text{cm}$, and WHO grade $1$, with no ductal dilation, vascular involvement, or nodal disease; institute MRI or pancreas-protocol CT every $6$ months for $2$ years then annually, with EUS if interval growth is suspected; proceed to resection if any of the following occur: growth $\\gt 0.5\\,\\text{cm}$ per year or $\\ge 20\\%$ diameter increase, size reaches $\\ge 2\\,\\text{cm}$, development of symptoms, new lymphadenopathy or duct dilation, or repeat sampling shows Ki-67 $\\ge 3\\%$.\n\nB. Proceed with immediate distal pancreatectomy with splenectomy because all nonfunctional pNETs in the tail that are $\\geq 1\\,\\text{cm}$ have an unacceptably high nodal metastasis rate; observation is not appropriate regardless of grade or imaging features.\n\nC. Perform enucleation without lymph node assessment because the lesion is $\\lt 2\\,\\text{cm}$ and low grade; no structured surveillance is necessary beyond a single postoperative CT at $12$ months given the low malignant potential.\n\nD. Observation is appropriate only in patients with prohibitive operative risk or age $\\geq 75$ years; otherwise, resect all nonfunctional pNETs $\\gt 1\\,\\text{cm}$; if observing, trigger surgery only if growth exceeds $1\\,\\text{mm}$ per year, as smaller changes fall within measurement error.",
            "solution": "The decision between observation and resection for small, incidentally identified, nonfunctional pancreatic neuroendocrine tumors (pNETs) should be derived from core oncologic principles and well-established clinical observations:\n\n1. Tumor biology and risk stratification: For well-differentiated pNETs, the risk of nodal and distant metastasis correlates with size and proliferative index. Nonfunctional pNETs that are $\\lt 2\\,\\text{cm}$ and WHO grade $1$ (Ki-$67 \\lt 3\\%$) have relatively indolent behavior and lower metastatic potential compared with larger or higher-grade tumors.\n\n2. Growth kinetics: Small, low-grade pNETs often exhibit slow growth. Surveillance frameworks rely on detecting clinically meaningful growth, commonly framed as an absolute increase (for example, $\\gt 0.5\\,\\text{cm}$ per year) or a relative increase (for example, $\\geq 20\\%$ in diameter), which exceeds typical inter-study measurement variability and correlates with biological progression.\n\n3. Anatomic and imaging features: Absence of main pancreatic duct dilation, vascular abutment or invasion, and lymphadenopathy on high-quality imaging reduces the likelihood of occult aggressive behavior and the need for immediate intervention.\n\n4. Surgical risk-benefit calculus: Distal pancreatectomy, even when spleen-preserving, carries nontrivial morbidity, including clinically relevant postoperative pancreatic fistula (on the order of approximately $10$–$20\\%$), and potential long-term endocrine (diabetes mellitus) and exocrine insufficiency. Splenectomy adds risks related to overwhelming post-splenectomy infection and requires vaccination. Avoiding surgery is reasonable if oncologic risk is low and the patient is reliable for surveillance.\n\n5. Patient factors: Absence of hormone excess symptoms (nonfunctional tumor), patient willingness and ability to adhere to surveillance, and lack of prohibitive comorbidity inform shared decision-making.\n\nApplying these principles to the presented patient with a $1.5\\,\\text{cm}$, nonfunctional, well-differentiated, WHO grade $1$ pNET without ductal dilation, vascular involvement, nodes, or metastasis, observation can be appropriate if a rigorous surveillance plan and clear intervention triggers are defined.\n\nOption-by-option analysis:\n\nA. This option articulates selection criteria for observation that align with the risk profile: nonfunctional status, size $\\lt 2\\,\\text{cm}$, WHO grade $1$ (Ki-$67 \\lt 3\\%$), and reassuring imaging (no ductal dilation, vascular involvement, or nodes). It also specifies a surveillance cadence (MRI or pancreas-protocol CT every $6$ months for $2$ years, then annually) that corresponds to capturing early growth while limiting radiation exposure; EUS can resolve uncertainties about growth or morphology. The intervention triggers (growth $\\gt 0.5\\,\\text{cm}$ per year or $\\geq 20\\%$ increase, size $\\geq 2\\,\\text{cm}$, new symptoms, new lymphadenopathy or duct dilation, or Ki-$67$ progression to $\\geq 3\\%$ on repeat sampling) are grounded in the distinction between indolent and more aggressive behavior and exceed known measurement error. This reflects a sound, evidence-aligned, risk-adaptive approach that balances oncologic safety with surgical morbidity. Verdict — Correct.\n\nB. This option mandates immediate resection and splenectomy for all tail pNETs $\\geq 1\\,\\text{cm}$ regardless of grade, functionality, or imaging. While the risk of nodal metastasis is not zero for small pNETs, high-quality data and consensus guidelines support consideration of active surveillance for selected nonfunctional, $\\lt 2\\,\\text{cm}$, well-differentiated tumors with reassuring imaging due to their relatively favorable biology and the morbidity of distal pancreatectomy. A blanket rule at the $1\\,\\text{cm}$ threshold disregards tumor grade and other risk-modifying features and overestimates the net benefit of surgery in many patients. Verdict — Incorrect.\n\nC. This option proposes enucleation without lymph node assessment and minimal follow-up. Although enucleation can be considered for small lesions that are exophytic and sufficiently distant from the main pancreatic duct, omission of lymph node assessment in nonfunctional pNETs risks under-staging because nodal metastasis can occur even in small tumors. Furthermore, advocating no structured surveillance after a single $12$-month scan neglects the potential for late growth or recurrence. This plan underestimates the need for appropriate staging and longitudinal evaluation. Verdict — Incorrect.\n\nD. This option restricts observation only to very elderly or prohibitive-risk patients and suggests a resection threshold of $\\gt 1\\,\\text{cm}$. It also proposes a growth trigger of $1\\,\\text{mm}$ per year, which is within the range of inter-study measurement variability for small pancreatic lesions and thus not a reliable biologic signal. Both the selection criteria and the trigger thresholds are miscalibrated relative to the biology of well-differentiated pNETs and the accuracy limits of imaging. Verdict — Incorrect.",
            "answer": "$$\\boxed{A}$$"
        }
    ]
}